Nephrogen

Nephrogen is a preclinical biotechnology company focused on developing curative genomic medicines specifically targeting kidney and pancreatic diseases. As a Stanford biotech spinout, the company is leveraging advanced technologies to address significant gaps in the treatment of these serious conditions. Currently, there are no approved gene-based therapies for kidney or pancreatic diseases, which affect a substantial portion of the population and contribute significantly to healthcare costs, particularly Medicare spending. Nephrogen's mission is to fill this void by creating effective genetic…